For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative expenses | 456,538 | 452,603.5 | 225,579 | 269,810 |
| Loss from operations | -456,538 | -452,603.5* | -225,579 | -269,810 |
| Change in fair value of over-allotment liability | - | 0* | - | - |
| Interest earned on cash held in trust account | 1,850,659 | 1,979,800* | 2,192,321 | 2,144,153 |
| Total other income | 1,850,659 | 1,979,800* | 2,192,321 | 2,144,153 |
| Net income | 1,394,121 | 1,527,196.5 | 1,966,742 | 1,874,343 |
| Basic EPS | 0.06 | 0.08 | 0.08 | - |
| Diluted EPS | 0.06 | 0.08 | 0.08 | - |
| Basic Average Shares | 19,199,029 | 19,199,029 | 19,199,029 | - |
| Diluted Average Shares | 19,199,029 | 19,199,029 | 19,199,029 | - |
Oaktree Acquisition Corp. III Life Sciences (OACC)
Oaktree Acquisition Corp. III Life Sciences (OACC)